This page is under construction and subject to change
A member of the Racetam family, a class of compounds famed for their cognition enhancing properties, it also shows promise as an antidepressant and anxiolytic.
These receptors are all associated with the formation and retention of new memories. This has been proven in the laboratory.
Primarily it has attracted the interest of Nootropics enthusiasts searching for ever stronger analogues of the original Racetam, Piracetam.
Fasoracetam improves general intelligence while attacking anxiety and apathy, which, as much as a lack of ability, can stand in the way of reaching one’s full potential.
These are also frequent concerns for patients diagnosed with ADHD which explains the interest in researching its effects for this disorder.
Fasoracetam prevents learned helplessness. In animal trials, rats given the drug were substantially less likely to remain immobile when submersed in water than those who were not. They were also more motivated to rescue themselves from merciless electrical shocks on their feet.
While human studies have yet to be conducted in this area, it was found to increase “the number of GABAB receptors in rat cerebral cortex without affecting the binding properties of Adrenoceptors and 5-HT2 receptors.”
This is remarkable. This means the brain does not, as several recreational users have reported, build a tolerance to Fasoracetam; each dose is as or more effective at alleviating depression and anxiety as the last. Its mechanism of action is not like Prozac’s (Reuptake Inhibitor).
Its antidepressant effects are most prominent at large doses and a standard dose has not yet been agreed upon. In human trials, 100mg a day has been given to subjects with no observed consequences, but some psychonauts use only 10mg a day sublingually.Nor does it affect monoamine uptake or its circulating concentration within tissues. Its short term safety has been established, but it is not certain whether it is as well tolerated long term as Piracetam or Aniracetam.
Fasoracetam (NS-105, LAM-105) was initially developed for the treatment of Alzheimers by Nippon Shinyaku.
The benefits of Fasoracetam are mostly in anecdote, but there are some studies to suggest a correlation. Given that there are millions of children and adolescents using amphetamine-based ADHD medication, studies testing Fasoracetam effects is a good sign. Even better, Fasoracetam has made it to phase II and III of clinical trials , which could suggest a high effectiveness for this purpose. As of June 2016, the drug was still in these trials.
According to anecdotal evidence on fasoracetam benefits, the concentration and stimulation benefits are moderate. One person likened the stimulation effects to Noopept and another said it was more of an energy boost than stimulation.
Aside from these focus and concentration related benefits, there is evidence for neuroprotective effects as well. One rat study showed that Fasoracetam could prevent memory disruptions. This is common amongst the Racetam line of drugs and makes sense that Fasoracetam would display many of these same properties.
Another interesting benefit of Fasoracetam is as an antidepressant and anxiolytic. A study of rats with learned helplessness showed that the drug had potent antidepressant effects without some of the side effects (such as MAOI interactions). This study concluded that GABA (B) up-regulation was able to increase test results in the animals.
There is no conclusive evidence as to how Fasoracetam works to improve cognition, but theories suggest it interacts with the cholinergic system and receptors of GABA and glutamate.
The GABA (B) up-regulation discussed in the benefits is another mechanism of action for the antidepressant and anxiety related benefits, but more information is needed to fully understand how Fasoracetam works regarding memory formation and stimulation.
There are currently no known side effects of Fasoracetam in the scientific literature, but that does not mean it is free from risks. Not only do any synthetic drugs come with risks, but anecdotal evidence in smart drug communities can tell us a few things about the drug.
For one, some anecdotal reports suggest reduction in orgasms. A specific individual has cited this effect, but seems rare and perhaps confounded with other variables.
Long time Nootropics users may think Fasoracetam is a joke (there seems to be a new one released every month), but this is a new synthetic compound that is part of the Racetam family. Synthesized in the 1960s, Piracetam was the first of the family and continues to be one of the more famous Nootropic drugs on the market.
No set dosing guidelines have been established. Most users report good results with 10-30 mg a day.
The anecdotal evidence suggests smaller doses range around 10 – 15 mg with larger doses in the 30 – 50 mg per serving three times per day.
The latter heavy dose was used by someone who tried using GABA up-regulation to resolve Phenibut withdrawal symptoms, however.